Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 28

1.

Cardiac adenylyl cyclase overexpression precipitates and aggravates age-related myocardial dysfunction.

Mougenot N, Mika D, Czibik G, Marcos E, Abid S, Houssaini A, Vallin B, Guellich A, Mehel H, Sawaki D, Vandecasteele G, Fischmeister R, Hajjar RJ, Dubois-Randé JL, Limon I, Adnot S, Derumeaux G, Lipskaia L.

Cardiovasc Res. 2019 Jan 3. doi: 10.1093/cvr/cvy306. [Epub ahead of print]

PMID:
30605506
2.

New Nitric Oxide Donor NCX 1443: Therapeutic Effects on Pulmonary Hypertension in the SAD Mouse Model of Sickle Cell Disease.

Abid S, Kebe K, Houssaïni A, Tomberli F, Marcos E, Bizard E, Breau M, Parpaleix A, Tissot CM, Maitre B, Lipskaia L, Derumeaux G, Bastia E, Mekontso-Dessap A, Adnot S.

J Cardiovasc Pharmacol. 2018 May;71(5):283-292. doi: 10.1097/FJC.0000000000000570.

PMID:
29438213
3.

mTOR pathway activation drives lung cell senescence and emphysema.

Houssaini A, Breau M, Kebe K, Abid S, Marcos E, Lipskaia L, Rideau D, Parpaleix A, Huang J, Amsellem V, Vienney N, Validire P, Maitre B, Attwe A, Lukas C, Vindrieux D, Boczkowski J, Derumeaux G, Pende M, Bernard D, Meiners S, Adnot S.

JCI Insight. 2018 Feb 8;3(3). pii: 93203. doi: 10.1172/jci.insight.93203. [Epub ahead of print]

4.

mTOR: A Key to Both Pulmonary Vessel Remodeling and Right Ventricular Function in Pulmonary Arterial Hypertension?

Houssaini A, Adnot S.

Am J Respir Cell Mol Biol. 2017 Nov;57(5):509-511. doi: 10.1165/rcmb.2017-0245ED. No abstract available.

PMID:
29090958
5.

Osteopontin, a Key Mediator Expressed by Senescent Pulmonary Vascular Cells in Pulmonary Hypertension.

Saker M, Lipskaia L, Marcos E, Abid S, Parpaleix A, Houssaini A, Validire P, Girard P, Noureddine H, Boyer L, Vienney N, Amsellem V, Marguerit L, Maitre B, Derumeaux G, Dubois-Rande JL, Jourdan-Lesaux C, Delcroix M, Quarck R, Adnot S.

Arterioscler Thromb Vasc Biol. 2016 Sep;36(9):1879-90. doi: 10.1161/ATVBAHA.116.307839. Epub 2016 Jul 21.

PMID:
27444202
6.

Role of interleukin-1 receptor 1/MyD88 signalling in the development and progression of pulmonary hypertension.

Parpaleix A, Amsellem V, Houssaini A, Abid S, Breau M, Marcos E, Sawaki D, Delcroix M, Quarck R, Maillard A, Couillin I, Ryffel B, Adnot S.

Eur Respir J. 2016 Aug;48(2):470-83. doi: 10.1183/13993003.01448-2015. Epub 2016 Jul 13.

7.

Selective Tuberous Sclerosis Complex 1 Gene Deletion in Smooth Muscle Activates Mammalian Target of Rapamycin Signaling and Induces Pulmonary Hypertension.

Houssaini A, Abid S, Derumeaux G, Wan F, Parpaleix A, Rideau D, Marcos E, Kebe K, Czibik G, Sawaki D, Treins C, Dubois-Randé JL, Li Z, Amsellem V, Lipskaia L, Pende M, Adnot S.

Am J Respir Cell Mol Biol. 2016 Sep;55(3):352-67. doi: 10.1165/rcmb.2015-0339OC.

PMID:
26991739
8.

Extracellular Calpain/Calpastatin Balance Is Involved in the Progression of Pulmonary Hypertension.

Wan F, Letavernier E, Abid S, Houssaini A, Czibik G, Marcos E, Rideau D, Parpaleix A, Lipskaia L, Amsellem V, Gellen B, Sawaki D, Derumeaux G, Dubois-Randé JL, Delcroix M, Quarck R, Baud L, Adnot S.

Am J Respir Cell Mol Biol. 2016 Sep;55(3):337-51. doi: 10.1165/rcmb.2015-0257OC.

PMID:
26974350
9.

Calpastatin overexpression impairs postinfarct scar healing in mice by compromising reparative immune cell recruitment and activation.

Wan F, Letavernier E, Le Saux CJ, Houssaini A, Abid S, Czibik G, Sawaki D, Marcos E, Dubois-Rande JL, Baud L, Adnot S, Derumeaux G, Gellen B.

Am J Physiol Heart Circ Physiol. 2015 Dec 1;309(11):H1883-93. doi: 10.1152/ajpheart.00594.2015. Epub 2015 Oct 9.

10.

Telomere Dysfunction and Cell Senescence in Chronic Lung Diseases: Therapeutic Potential.

Adnot S, Amsellem V, Boyer L, Marcos E, Saker M, Houssaini A, Kebe K, Dagouassat M, Lipskaia L, Boczkowski J.

Pharmacol Ther. 2015 Sep;153:125-34. doi: 10.1016/j.pharmthera.2015.06.007. Epub 2015 Jun 18. Review.

PMID:
26096607
11.

Endothelial-to-mesenchymal transition in pulmonary hypertension.

Ranchoux B, Antigny F, Rucker-Martin C, Hautefort A, Péchoux C, Bogaard HJ, Dorfmüller P, Remy S, Lecerf F, Planté S, Chat S, Fadel E, Houssaini A, Anegon I, Adnot S, Simonneau G, Humbert M, Cohen-Kaminsky S, Perros F.

Circulation. 2015 Mar 17;131(11):1006-18. doi: 10.1161/CIRCULATIONAHA.114.008750. Epub 2015 Jan 15.

PMID:
25593290
12.

Role for telomerase in pulmonary hypertension.

Mouraret N, Houssaïni A, Abid S, Quarck R, Marcos E, Parpaleix A, Gary-Bobo G, Dubois-Randé JL, Derumeaux G, Boczkowski J, Delcroix M, Blasco MA, Lipskaia L, Amsellem V, Adnot S.

Circulation. 2015 Feb 24;131(8):742-755. doi: 10.1161/CIRCULATIONAHA.114.013258. Epub 2014 Dec 30.

13.

CCR5 as a treatment target in pulmonary arterial hypertension.

Amsellem V, Lipskaia L, Abid S, Poupel L, Houssaini A, Quarck R, Marcos E, Mouraret N, Parpaleix A, Bobe R, Gary-Bobo G, Saker M, Dubois-Randé JL, Gladwin MT, Norris KA, Delcroix M, Combadière C, Adnot S.

Circulation. 2014 Sep 9;130(11):880-891. doi: 10.1161/CIRCULATIONAHA.114.010757. Epub 2014 Jul 3.

14.

P21-dependent protective effects of a carbon monoxide-releasing molecule-3 in pulmonary hypertension.

Abid S, Houssaïni A, Mouraret N, Marcos E, Amsellem V, Wan F, Dubois-Randé JL, Derumeaux G, Boczkowski J, Motterlini R, Adnot S.

Arterioscler Thromb Vasc Biol. 2014 Feb;34(2):304-12. doi: 10.1161/ATVBAHA.113.302302. Epub 2013 Dec 12.

PMID:
24334871
15.

Serotonin transporter and serotonin receptors.

Adnot S, Houssaini A, Abid S, Marcos E, Amsellem V.

Handb Exp Pharmacol. 2013;218:365-80. doi: 10.1007/978-3-642-38664-0_15. Review.

PMID:
24092348
16.

A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure.

Marcelin AG, Delaugerre C, Beaudoux C, Descamps D, Morand-Joubert L, Amiel C, Schneider V, Ferre V, Izopet J, Si-Mohamed A, Maillard A, Henquell C, Desbois D, Lazrek M, Signori-Schmuck A, Rogez S, Yerly S, Trabaud MA, Plantier JC, Fourati S, Houssaini A, Masquelier B, Calvez V, Flandre P; ANRS AC11 Resistance Group.

Int J Antimicrob Agents. 2013 Jul;42(1):42-7. doi: 10.1016/j.ijantimicag.2013.02.016. Epub 2013 Apr 4.

PMID:
23562640
17.

Scoring methods for building genotypic scores: an application to didanosine resistance in a large derivation set.

Houssaini A, Assoumou L, Miller V, Calvez V, Marcelin AG, Flandre P.

PLoS One. 2013;8(3):e59014. doi: 10.1371/journal.pone.0059014. Epub 2013 Mar 21.

18.

Activation of lung p53 by Nutlin-3a prevents and reverses experimental pulmonary hypertension.

Mouraret N, Marcos E, Abid S, Gary-Bobo G, Saker M, Houssaini A, Dubois-Rande JL, Boyer L, Boczkowski J, Derumeaux G, Amsellem V, Adnot S.

Circulation. 2013 Apr 23;127(16):1664-76. doi: 10.1161/CIRCULATIONAHA.113.002434. Epub 2013 Mar 19.

19.

Rapamycin reverses pulmonary artery smooth muscle cell proliferation in pulmonary hypertension.

Houssaini A, Abid S, Mouraret N, Wan F, Rideau D, Saker M, Marcos E, Tissot CM, Dubois-Randé JL, Amsellem V, Adnot S.

Am J Respir Cell Mol Biol. 2013 May;48(5):568-77. doi: 10.1165/rcmb.2012-0429OC.

20.

HIV-1 integrase variability and relationship with drug resistance in antiretroviral-naive and -experienced patients with different HIV-1 subtypes.

Reigadas S, Marcelin AG, Houssaïni A, Yerly S, Descamps D, Plantier JC, Ruffault A, Amiel C, Trabaud MA, Flandre P, Fleury H, Masquelier B; ANRS AC11 Resistance Study Group.

J Antimicrob Chemother. 2013 Apr;68(4):969-72. doi: 10.1093/jac/dks474. Epub 2012 Nov 25. No abstract available.

PMID:
23184711

Supplemental Content

Loading ...
Support Center